Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
Public ClinicalTrials.gov record NCT02013531. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Protocol 331-13-002: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in subjects with major depressive disorder and anxiety symptoms, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin norepinephrine reuptake inhibitor (SNRI) response.
Study identification
- NCT ID
- NCT02013531
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 37 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2013 (Type not available)
- Primary completion
- May 2014 (Actual)
- Completion
- Jun 2014 (Actual)
- Last update posted
- Mar 29, 2016
2013 – 2014
United States locations
- U.S. sites
- 21
- U.S. states
- 14
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tuscon | Arizona | 85712 | — |
| Not listed | Garden Grove | California | 92845 | — |
| Not listed | Oceanside | California | 92056 | — |
| Not listed | Temecula | California | 92591 | — |
| Not listed | Gainesville | Florida | 32607 | — |
| Not listed | Jacksonville | Florida | 32256 | — |
| Not listed | Miami | Florida | 33145 | — |
| Not listed | Atlanta | Georgia | 30308 | — |
| Not listed | Lafayette | Indiana | 47905 | — |
| Not listed | Baltimore | Maryland | 21208 | — |
| Not listed | Boston | Massachusetts | 02131 | — |
| Not listed | Haverhill | Massachusetts | 01830 | — |
| Not listed | Rochester Hills | Michigan | 48307 | — |
| Not listed | New York | New York | 10168 | — |
| Not listed | Staten Island | New York | 10305 | — |
| Not listed | Salem | Oregon | 97301 | — |
| Not listed | Allentown | Pennsylvania | 18104 | — |
| Not listed | Arlington | Texas | 76012 | — |
| Not listed | Austin | Texas | 78731 | — |
| Not listed | Woodstock | Vermont | 05091 | — |
| Not listed | Richmond | Virginia | 23230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02013531, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 29, 2016 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02013531 live on ClinicalTrials.gov.